🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Abeona Therapeutics director sells over $116k in company stock

Published 06/20/2024, 04:32 PM

A recent filing with the Securities and Exchange Commission has revealed that Christine Berni Silverstein, a director of Abeona Therapeutics Inc. (NASDAQ:ABEO), has sold a significant number of shares in the company. The transaction, which took place on June 18, 2024, involved Silverstein selling 25,821 shares of common stock at a weighted average price of $4.51 per share, resulting in a total sale value of $116,452.

The sale was reportedly made to cover tax obligations that arose from the vesting of restricted stock awards, as indicated by a footnote in the filing. Investors were also informed that the shares were sold in multiple transactions with prices ranging from $4.47 to $4.55. After the sale, Silverstein still retains a total of 62,063 shares in the company, signifying a continued investment in Abeona Therapeutics' future.

Abeona Therapeutics, a biopharmaceutical company based in Cleveland, Ohio, is known for its work in developing gene and cell therapies for life-threatening rare genetic diseases. Silverstein's transaction comes at a time when insider trading activities are closely watched by investors for insights into executive confidence and company performance.

The company has a history that includes name changes and rebranding, having previously been known as PlasmaTech Biopharmaceuticals Inc., Access Pharmaceuticals Inc., and Chemex Pharmaceuticals Inc. Abeona Therapeutics is incorporated in Delaware and has its fiscal year end on December 31.

Investors and stakeholders can request more detailed information about the exact prices at which the shares were sold within the reported range by contacting the issuer, any security holder of the issuer, or the SEC staff, as per the reporting person's undertaking.

"In other recent news, Abeona Therapeutics has been in the spotlight with several significant developments. Stifel, a financial services company, has initiated coverage on Abeona Therapeutics, assigning a Buy rating and establishing a price target of $21.00. This comes as Abeona continues to advance its novel treatment for recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin disorder.

In connection with funding, Abeona Therapeutics recently set terms for a $75 million stock offering. This move is expected to raise substantial capital to fund the company's operations, including preparations for the resubmission of its Biologics License Application (BLA) and commercialization efforts for its product candidate, pz-cel.

However, the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Abeona, requesting additional data concerning its BLA for pz-cel. Abeona's CEO, Vish Seshadri, has expressed commitment to addressing the FDA's requirements, with the company planning to resubmit the BLA in the third quarter of 2024. These are among the recent developments concerning Abeona Therapeutics."

InvestingPro Insights

In light of the recent insider trading activity by Christine Berni Silverstein at Abeona Therapeutics Inc. (NASDAQ:ABEO), a deeper dive into the company's financial metrics can provide investors with additional context. According to real-time data from InvestingPro, Abeona Therapeutics currently holds a market capitalization of $185.15 million. Despite a notable revenue growth of 227.72% in the last twelve months as of Q1 2024, the company has reported a gross profit margin of -810.34%, indicating that it is spending significantly more to produce its goods than it is earning from sales.

The company's stock price volatility is reflected in a three-month price total return of -39.71%, underscoring the fluctuations that investors may need to consider. Moreover, an InvestingPro Tip highlights that Abeona Therapeutics is trading at a high revenue valuation multiple, which, when combined with the lack of profitability over the last twelve months and the anticipation by analysts that the company will not be profitable this year, suggests a cautious approach for potential investors.

For those looking to delve further into the financial health and future prospects of Abeona Therapeutics, InvestingPro offers additional insights. There are six more InvestingPro Tips available, which could be pivotal in making an informed decision. To access these tips and a wealth of other financial data, consider subscribing to InvestingPro. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.